口服萝卜硫素抑制NLRP3炎症小体可减轻急性痛风性炎症
该研究在两种MSU晶体诱导的急性痛风小鼠模型中,观察口服萝卜硫素(SFN)对NLRP3炎症小体的抑制作用。结果显示SFN减轻足垫肿胀和中性粒细胞募集,抑制caspase-1(p10)和IL-1β产生,并在原代巨噬细胞中抑制MSU、ATP和尼日利亚菌素诱导的NLRP3激活。作者认为口服SFN可能有助于预防急性痛风发作。
要点
- 口服SFN减轻MSU晶体诱导的小鼠足部肿胀和中性粒细胞募集。
- SFN抑制足组织和气囊模型中MSU诱导的NLRP3炎症小体激活。
- SFN在原代巨噬细胞中抑制NLRP3激活,且不依赖活性氧通路。
核心结论
- 口服SFN通过抑制NLRP3炎症小体有效减轻急性痛风性炎症,作者认为口服SFN可能有益于预防急性痛风发作。
研究设计与样本
- 研究在两种由MSU晶体注射诱导的急性痛风小鼠模型(足垫和气囊)中检验口服SFN的效果。
- 用免疫印迹和ELISA检测caspase-1(p10)和IL-1β产生作为NLRP3炎症小体激活的标志。
- 在原代小鼠巨噬细胞中检验SFN对MSU晶体、三磷酸腺苷和尼日利亚菌素及poly(dA:dT)诱导的NLRP3激活的影响。
主要发现
- 口服SFN减轻MSU晶体诱导的小鼠足部急性痛风模型肿胀和中性粒细胞募集,与足组织NLRP3炎症小体激活受抑制相关。
- 口服SFN在MSU晶体诱导的小鼠气囊痛风模型中阻断NLRP3炎症小体激活。
- SFN在原代小鼠巨噬细胞中抑制MSU晶体、三磷酸腺苷和尼日利亚菌素诱导的NLRP3炎症小体激活,但不抑制poly(dA:dT)诱导的激活,且不依赖活性氧通路。
- SFN抑制不依赖配体的NLRP3炎症小体激活,提示SFN可能直接作用于NLRP3炎症小体复合物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome. In this study, we investigated whether oral administration of an NLRP3 inhibitor would be effective to attenuate the symptoms of gout. METHODS: The effects of oral administration with sulforaphane (SFN) were examined in two mouse models of acute gout induced by injection of MSU crystals into footpads or air pouch. The production of caspase-1 (p10) and IL-1β was examined by immunoblotting and ELISA as hallmarks of NLRP3 inflammasome activation. RESULTS: Oral administration of SFN attenuated MSU crystal-induced swelling and neutrophil recruitment in a mouse foot acute gout model, correlating with the suppression of the NLRP3 inflammasome activation in foot tissues. Consistently, oral administration of SFN blocked MSU-crystal-induced activation of the NLRP3 inflammasome in a mouse air pouch gout model. SFN suppressed NLRP3 inflammasome activation induced by MSU crystals, adenosine triphosphate and nigericin but not by poly(dA:dT) in primary mouse macrophages, independent of the reactive oxygen species pathway. SFN inhibited ligand-independent activation of the NLRP3 inflammasome, suggesting that SFN may act directly on the NLRP3 inflammasome complex. CONCLUSION: Oral administration of SFN effectively alleviated acute gouty inflammation by suppression of the NLRP3 inflammasome. Our results provide a novel strategy in which oral treatment with SFN may be beneficial in preventing acute attacks of gout.
引用
- Yang G, Yeon SH, Lee HE, et al. Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. Rheumatology (Oxford). 2018. PMID: 29340626. doi:10.1093/rheumatology/kex499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。